Free Trial
OTCMKTS:TLPPF

Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis

Telix Pharmaceuticals logo
$15.90 -0.10 (-0.63%)
(As of 12/20/2024 05:55 PM ET)

About Telix Pharmaceuticals Stock (OTCMKTS:TLPPF)

Key Stats

Today's Range
$15.85
$15.90
50-Day Range
$13.34
$16.72
52-Week Range
$6.16
$16.74
Volume
8,250 shs
Average Volume
6,854 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Receive TLPPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TLPPF Stock News Headlines

Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 1.8% - Here's Why
Telix Pharmaceuticals Ltd. (TLPPF) Gets a Buy from UBS
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Telix Pharmaceuticals Updates Securities Policy Amid Market Interest
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals Ltd. (TLPPF)
See More Headlines

TLPPF Stock Analysis - Frequently Asked Questions

Telix Pharmaceuticals' stock was trading at $6.8750 at the beginning of 2024. Since then, TLPPF stock has increased by 131.3% and is now trading at $15.90.
View the best growth stocks for 2024 here
.

Shares of TLPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:TLPPF
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (OTCMKTS:TLPPF) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners